Department of Dermatology, The Second Xiangya Hospital of Central South University; Hunan Key Laboratory of Medical Epigenomics , Changsha, Hunan, China.
Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences , Changsha, Hunan, China.
Expert Rev Clin Immunol. 2020 Aug;16(8):829-837. doi: 10.1080/1744666X.2020.1805316. Epub 2020 Sep 29.
Between 5 and 25% of patients with cutaneous lupus erythematosus (CLE) can progress to systemic lupus erythematosus (SLE) during the course of the disease. There is no clear predictive guideline for the progression of CLE to SLE.
Lupus erythematosus (LE), a chronic autoimmune disease, has a wide spectrum of manifestations. On one side of the spectrum is CLE, in which patients only display skin lesions. On the other side of the spectrum is SLE, which develops severe systemic involvement. CLE has even been considered as a separate entity from LE, while CLE is also proposed to be associated with SLE. In this review, the authors will describe the relationship between CLE and SLE; summarize the incidence, risk factors, systemic involvement, and management of patients who transition to SLE. The literature search was conducted mainly through PubMed from March to July 2020.
The identification of clinical characteristics and biomarkers in patients facing risk of developing SLE and monitoring the disease on a regular basis are essential to promptly manage and hopefully prevent transition to the systemic form.
在疾病过程中,5%至 25%的皮肤红斑狼疮(CLE)患者可能进展为系统性红斑狼疮(SLE)。目前尚无CLE 进展为 SLE 的明确预测指南。
红斑狼疮(LE)是一种慢性自身免疫性疾病,具有广泛的表现。一方面是 CLE,患者仅表现为皮肤损伤。另一方面是 SLE,其发展为严重的全身受累。CLE 甚至被认为是 LE 的一个独立实体,而 CLE 也被认为与 SLE 有关。在这篇综述中,作者将描述 CLE 和 SLE 之间的关系;总结向 SLE 转变的患者的发生率、风险因素、系统受累和治疗。文献检索主要通过 2020 年 3 月至 7 月期间的 PubMed 进行。
识别处于 SLE 发病风险的患者的临床特征和生物标志物,并定期监测疾病,对于及时管理并希望预防疾病向系统性转变至关重要。